Later-Line Therapy in Multiple Myeloma

A real-world analysis showed that 56 mg/m2 of carfilzomib once weekly offered many benefits over 56 mg/m2 twice weekly and 70 mg/m2 once weekly in myeloma.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Modakafusp alfa induced the upregulation of the type 1 interferon gene signature score, and increased CD38 receptor density in CD-38–positive cells.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone was well tolerated in patients with relapsed/refractory multiple myeloma.

Final OS analysis data from the OPTIMISMM trial support sequencing a pomalidomide-based regimen after lenalidomide failure in relapsed/refractory myeloma.